Blood biomarker profiles and exceptional longevity: comparison of centenarians and non-centenarians in a 35-year follow-up of the Swedish AMORIS cohort.
Level 3 - non-randomized controlled study
Prospective population-based cohort study with long-term register follow-up
PubMed 37726432 · doi:10.1007/s11357-023-00936-w
What was done
Participants in the Swedish population-based AMORIS cohort with blood biomarkers measured between 1985 and 1996 were followed in Swedish register data for up to 35 years. Biomarkers reflecting metabolism, inflammation, liver, renal, anemia, and nutritional status measured between ages 64 and 99 were compared between individuals who eventually reached age 100 and their shorter-lived peers using descriptive statistics, logistic regression, and cluster analysis.
What was found
In total, 1,224 participants (84.6% female) lived to their 100th birthday. Reaching age 100 was associated with higher levels of total cholesterol and iron, and lower levels of glucose, creatinine, uric acid, aspartate aminotransferase, gamma-glutamyl transferase, alkaline phosphatase, lactate dehydrogenase, and total iron-binding capacity. Centenarians displayed generally homogenous biomarker profiles and more favorable biomarker values starting from age 65 and onwards compared to individuals dying before age 100. Numerical effect sizes, odds ratios, and confidence intervals were not reported in the abstract.
Why it matters
This study shows that differences in standard, readily measurable metabolic, hepatic, and renal biomarkers are detectable decades prior to extreme old age, highlighting physiological profiles linked to exceptional longevity.
Limits
The total sample size of the non-centenarian comparison group is not reported in the abstract, nor are numerical effect sizes or confidence intervals provided. The observational design cannot establish causality between biomarker levels and lifespan, and results from a Swedish cohort may not generalize to other populations.
Cited by
- supports The AMORIS study from Sweden demonstrated that uric acid levels and blood glucose control were predictive biomarkers of longevity.